Remdesivir, dexamethasone, and baricitinib have recently been used to treat patients with coronavirus disease 2019 (COVID-19) and respiratory failure. However, the adverse effects of combination therapy have not been fully explored. A 64-year-old man was diagnosed with COVID-19 and was treated with remdesivir, dexamethasone, and baricitinib. His respiratory condition worsened on day 17, and in the following days, he was diagnosed with pneumomediastinum and COVID-19-associated pulmonary aspergillosis (CAPA). His condition improved with a reduction in the corticosteroid regime and antifungal treatment. This is the first case of pulmonary aspergillosis in a patient with COVID-19 that was treated with remdesivir, dexamethasone, and baricitinib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064704 | PMC |
| http://dx.doi.org/10.7759/cureus.23755 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of X-Linked Agammaglobulinemia and COVID-19 in a Japanese Infant.
J Nippon Med Sch
January 2025
Department of Pediatrics, Nippon Medical School.
An infant was diagnosed as having X-linked agammaglobulinemia (XLA) at age 3 months and was receiving immunoglobulin replacement therapy. He developed SARS-CoV-2 infection at age 7 months and was treated with intravenous immunoglobulin, remdesivir, and dexamethasone. His respiratory symptoms improved quickly, and the infection resolved.
View Article and Find Full Text PDFAnnual SZ: An Alternative Immunotherapy for COVID-19 and Long COVID.
Infect Disord Drug Targets
December 2024
Department of Immunology, Faculty of Medical Sciences, Tarbiat Modarres University, Tehran, Iran.
Since the outbreak of coronavirus disease 2019 (COVID-19) in late 2019 and early 2020, the identification of drugs to control severe acute respiratory syndrome coro-navirus 2 (SARS-CoV-2) infection and its symptoms has been a pressing focus of research. Cytokine storm and acute respiratory distress syndrome (ARDS) are the leading causes of mortality following infection. In this review, we discuss immune pathogenesis and four medications, including Remdesivir, Tocilizumab, Dexamethasone, and Annual SZ for COVID-19.
View Article and Find Full Text PDFA case of severe Covid-19 infection as the first manifestation of Cushing's disease.
Endocrinol Diabetes Metab Case Rep
October 2024
Department of Endocrinology, Hospital Egas Moniz, CHLO, Lisbon, Portugal.
Article Synopsis
- * A 20-year-old male with undiagnosed CD experienced critical health issues during a severe COVID-19 infection, requiring intensive care and showcasing classic signs of hypercortisolism, leading to further diagnostic testing.
- * After surgical intervention for CD, the patient showed significant health improvements, including better body composition and mood, highlighting the importance of early recognition and timely treatment of hypercortisolism to prevent serious complications.
Clinical usefulness of the serum levels of neuroinflammatory and lung fibrosis biomarkers in the assessment of cognitive dysfunction in post-COVID19 patients.
Sci Rep
October 2024
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, 15-540, Białystok, Poland.
A growing body of evidence indicates there is an increasing incidence of cognitive dysfunction in patients after coronavirus disease 2019 (COVID-19) infection. However, still lack diagnostic tools, which allow us to predict prognosis in such cases and improve the stratification of the disease. This study aims to evaluate the usefulness of the biomarkers that could allow to predict the severity and progression of COVID-19 in patients with post-COVID syndrome and cognitive problems.
View Article and Find Full Text PDFThe Effectiveness and Safety of Remdesivir Use in COVID-19 Patients with Neutropenia: A Retrospective Cohort Study.
Life (Basel)
October 2024
Department of Emergency Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan.
Background: The COVID-19 pandemic poses severe risks for immunocompromised patients, especially those with neutropenia due to chemotherapy. This study evaluates the safety and effectiveness of remdesivir use in COVID-19 patients with neutropenia.
Methods: This retrospective study used the Chang Gung Research Database (CGRD) and extracted data from 98,763 patients with COVID-19 diagnosed between April 2021 and September 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!